Femoston 2 10 can I drink alcohol? How to drink femoston correctly and its possible side effects

Taking hormonal medications lasts quite a long time. Long-term treatment forces a person to change his habits and monitor his health more carefully.

So that therapy can give positive result, you should discuss with your doctor in advance all possible nuances of nutrition, whether you can drink alcohol during this period or not.

It is impossible to predict how alcohol will behave along with taking Femoston tablets, because alcoholic beverages are the first thing that the doctor strongly recommends limiting.

Hormones are responsible for the vital functions of the human body. Their production occurs on the principle of replacement: if somewhere their level decreases, then a specific gland internal secretion begins active production. Where there are not enough hormones, the organ’s performance deteriorates, and where there is an excess, hyperactivity occurs. Neither one nor the other brings any benefit to a person. There are three types of hormone therapy available:

• blocking – inhibits the active work of the glands;
• stimulating – enhances endocrine glands with decreased activity;
• replacement – ​​used in the complete absence of a certain type of hormone.

Prescriptions of the drug Femoston

The drug Femoston is a hormone replacement therapy. Its composition is synthetic, active substances estradiol and dydrogesterone - analogues of the female sex hormones estradiol and progesterone.

Progesterone affects the growth, development of the fetus, and pregnancy. Estradiol is responsible for the psycho-emotional and vegetative background of a woman during menopause.

The doctor prescribes Femoston to women who have entered the stage age-related changes and associated psycho-emotional disorders: rapid heartbeat, hot flashes, sleep disturbances, for the prevention of osteoporosis, which is a very common manifestation of menopausal changes

The drug is also prescribed to women who, for a number of reasons, have failed to become pregnant.

Before prescribing a medicine to a patient, the doctor must collect full complex medical tests, will hold gynecological examination for hidden contraindications and identified diseases.

During direct administration of Femoston, it is recommended to conduct periodic examinations and pay attention to clinical changes in organism.

Forms of release of the drug

Pharmacies supply three types of medicine:

• Femoston 1/10;
• Femoston 1/5 conti;

Any form of the medication is available in tablet form, intended for oral administration. The difference in labeling is due to the nominal dosage of active substances, which allows each woman to choose the optimal option for taking the drug.

The package contains 28 colored pills different colors: orange and pink for the 1/5 variety, white and gray are packaged in 1/10, for the 2/10 variety, the colors will be light yellow, pink.

The different color palette is not accidental - each color has a specific hormone assigned to it:

• white, pink contain estradiol;
• orange, gray and light yellow contain the hormone progesterone (dydrogesterone).

Accordingly, tablets are taken strictly according to color differentiation.

Features of taking Femoston tablets

Hormone replacement therapy with Femoston does not affect driving and, according to patients, is well tolerated by the body.

However, you should use the drug with caution as it has several side effects. None of the forms of the medicine can be used during pregnancy or breastfeeding.

The medicine is prescribed with caution to patients suffering from renal failure, heart failure, and chronic liver diseases (Femoston 2/10).

• breast cancer;
• any forms of estrogen-dependent formations;
• internal bleeding;
• presence of thrombophlebitis;
• allergic intolerance to the components of the drug;
• threat of cerebrovascular accident.

The drug can be used in combination with other medications. However, it should be taken into account that medications containing St. John's wort will enhance the chemical and biological process of estrogen and progesterone. Together with antiviral anti-HIV drugs, the inducer reaction will increase, and simultaneous use with phenytoin and rifabutin, on the contrary, will significantly weaken the work of replacement therapy.

Combined use of Femoston with alcohol

Taking hormonal pills causes endocrine system work in a slightly different mode. The body can respond adverse reaction: migraine, nausea, cycle disorders. Excessive nervousness, exacerbation cholelithiasis, convulsions, swelling, liver dysfunction, Bladder. Especially Hard case will lead to stroke, Quincke's edema, hemolytic anemia.

The combination of Femoston and alcohol increases adverse reactions.

If you drink alcohol and take hormones at the same time, you can develop a number of serious complications. When absorbed into the blood, alcohol stimulates the production of prolactin. The person becomes overly excited, aggressive, signs appear depressive state, panic fear.

The compatibility of Femoston with ethyl alcohol will negate the therapeutic effect of the medication and increase the risk of developing osteoporosis. Menopausal complications, which the drug normalizes, will get out of control, increasing their effect. Additionally, problems with the thyroid gland will appear, weight will increase, and hirsutism will develop (hair growth will increase).

The most harmless of the side effects is a decrease in medicinal properties drug.

Rules for drinking alcohol

Nobody encourages you to give up alcoholic beverages without a categorical doctor’s prescription. You should take into account all the nuances and follow the rules of admission:

1. the maximum permissible dose of ethanol is 40 grams per week (100 grams of vodka, 400 grams of wine, 400 grams of beer);
2. break between pills and alcohol – 4.5 hours;
3. excess permissible norm more than 1.5 times, a justified reason to skip taking pills for 2 days.

Taking hormonal medications lasts quite a long time. Long-term treatment forces a person to change his habits and monitor his health more carefully.

In order for the therapy to give a positive result, you should discuss in advance with your doctor all possible nuances of nutrition, whether you can drink alcohol during this period or not.

It is impossible to predict how alcohol will behave along with taking Femoston tablets, because alcoholic beverages are the first thing that the doctor strongly recommends limiting.

Hormones are responsible for the vital functions of the human body. Their production occurs on the principle of replacement: if somewhere their level decreases, then a specific endocrine gland begins active production. Where there are not enough hormones, the organ’s performance deteriorates, and where there is an excess, hyperactivity occurs. Neither one nor the other brings any benefit to a person. There are three types of hormone therapy available:

• blocking – inhibits the active work of the glands;
• stimulating – strengthens the endocrine glands with decreased activity;
• replacement – ​​used in the complete absence of a certain type of hormone.

Prescriptions of the drug Femoston

The drug Femoston is a hormone replacement therapy. Its composition is synthetic, active substances estradiol and dydrogesterone - analogues of the female sex hormones estradiol and progesterone.

Progesterone affects the growth, development of the fetus, and pregnancy. Estradiol is responsible for the psycho-emotional and vegetative background of a woman during menopause.

The doctor prescribes Femoston for women who have entered the stage of age-related changes and associated psycho-emotional disorders: rapid heartbeat, hot flashes, sleep disturbances, for the prevention of osteoporosis, which is a very common manifestation of menopausal changes

The drug is also prescribed to women who, for a number of reasons, have failed to become pregnant.

Before prescribing a medicine to a patient, the doctor will necessarily collect a full range of medical tests and conduct a gynecological examination for hidden contraindications and identified diseases.

During direct administration of Femoston, it is recommended to conduct periodic examinations and pay attention to clinical changes in the body.

Forms of release of the drug

Pharmacies supply three types of medicine:

• Femoston 1/10;
• Femoston 1/5 conti;

Any form of the medication is available in tablet form, intended for oral administration. The difference in labeling is due to the nominal dosage of active substances, which allows each woman to choose the optimal option for taking the drug.

The package contains 28 pills colored in different colors: orange and pink for the 1/5 form, white and gray are packaged in 1/10, for the 2/10 variety, the colors will be light yellow, pink.

The different color palette is not accidental - each color has a specific hormone assigned to it:

• white, pink contain estradiol;
• orange, gray and light yellow contain the hormone progesterone (dydrogesterone).

Accordingly, tablets are taken strictly according to color differentiation.

Features of taking Femoston tablets

Hormone replacement therapy with Femoston does not affect driving and, according to patients, is well tolerated by the body.

However, you should use the drug with caution as it has several side effects. None of the forms of the medicine can be used during pregnancy or breastfeeding.

The medicine is prescribed with caution to patients suffering from renal failure, heart failure, and chronic liver diseases (Femoston 2/10).

• breast cancer;
• any forms of estrogen-dependent formations;
• internal bleeding;
• presence of thrombophlebitis;
• allergic intolerance to the components of the drug;
• threat of cerebrovascular accident.

The drug can be used in combination with other medications. However, it should be taken into account that medications containing St. John's wort will enhance the chemical and biological process of estrogen and progesterone. Together with antiviral anti-HIV drugs, the inducer reaction will increase, and simultaneous use with phenytoin and rifabutin, on the contrary, will significantly weaken the work of replacement therapy.

Combined use of Femoston with alcohol

Taking hormonal pills forces the endocrine system to work in a slightly different mode. The body may respond with an adverse reaction: migraine, nausea, cycle disruption. Excessive nervousness, exacerbation of cholelithiasis, convulsions, swelling, disruption of the liver and bladder. A particularly severe case will lead to stroke, angioedema, and hemolytic anemia.

The combination of Femoston and alcohol increases adverse reactions.

If you drink alcohol and take hormones at the same time, you can develop a number of serious complications. When absorbed into the blood, alcohol stimulates the production of prolactin. The person becomes overly excited, aggressive, signs of depression and panic appear.

The compatibility of Femoston with ethyl alcohol will negate the therapeutic effect of the medication and increase the risk of developing osteoporosis. Menopausal complications, which the drug normalizes, will get out of control, increasing their effect. Additionally, problems with the thyroid gland will appear, weight will increase, and hirsutism will develop (hair growth will increase).

The most harmless of the side effects is a decrease in the medicinal properties of the drug.

Rules for drinking alcohol

Nobody encourages you to give up alcoholic beverages without a categorical doctor’s prescription. You should take into account all the nuances and follow the rules of admission:

1. the maximum permissible dose of ethanol is 40 grams per week (100 grams of vodka, 400 grams of wine, 400 grams of beer);
2. break between pills and alcohol – 4.5 hours;
3. exceeding the permissible norm by more than 1.5 times is a justified reason to skip taking pills for 2 days.

THE BEGINNING OF CHANGE

Menopause is often called a life change. Menopause - new stage a woman’s life, the emergence of new opportunities, a chance to generalize life experience and, possibly, achieve new successes. How to save good health and well-being long years ? To be ready for possible problems and be able to overcome them, you need to know about them and do

right choice

already now, in the “transition period”. WHAT ARE HORMONES? Hormones are
chemical substances
, “intermediaries” between various organs and tissues of our body. Hormones are synthesized by endocrine glands. The finished hormone enters the blood and becomes a signal for the “target” organ, starting its function or stopping its work. Sex hormones are responsible not only for reproductive function, but also for everything that makes a woman a woman and a man a man. The main female sex hormones are estrogens and progesterone, which are synthesized in a woman’s ovaries. The production of estrogen and progesterone changes throughout life. IN reproductive age Hormones are synthesized cyclically, forming the so-called menstrual cycle. In the first phase of the cycle, estrogens are produced in the ovaries, and the hormone is produced in the second phase
Ovarian hormones (estrogens and progesterone), entering the blood, affect the entire body, ensuring the proper development of the genital organs, the formation of the mammary glands, a woman’s physique, the timbre of her voice, and also protects the woman’s cardiovascular system from atherosclerosis and much more.

WHAT HAPPENS WITH AGE?

When approaching menopause, reproductive function fades away, the production of sex hormones (estrogens and progesterone) decreases, menstruation stops. The last menstruation in a woman's life is called menopause.
Menopause usually occurs at 50-52 years of age. However, this stage can occur at 45 or even 35 years old.

• For most women, menopause does not come suddenly, but there are symptoms that indicate its approach:
• Changes in the nature of menstruation (they become scanty or, on the contrary, heavy) Irregular menstruation
• (breaks of up to several months are possible)

The appearance of “symptoms of menopause” The transition period in a woman’s life is the period of the most pronounced hormonal changes

and covers several years before menopause and the first 1.5-2 years after its onset. Not all women are the same; every woman experiences this period of life differently.

WHAT ARE THE SYMPTOMS? Menopausal symptoms are varied. Hot flashes night sweats , dizziness, sleep disturbances are usually transient, but can persist for several years until the body adapts to low hormone levels. Emotional disorders such as irritability, lack of self-confidence and/or Bad mood

, can also be a direct or indirect result of hormonal changes characteristic of menopause. A little later, dryness in the vagina, pain during sexual intercourse, and urination problems occur. These symptoms do not disappear on their own, but only intensify over time. The most serious

long-term consequence

Low estrogen levels result in bone loss (osteoporosis) and resulting bone fractures. WHAT IS OSTEOPOROSIS AND IS IT POSSIBLE TO PREVENT BONE LOSS? Osteoporosis means “porous bone.” Due to estrogen deficiency, the bone structure becomes less dense and bone strength decreases. Strength reduction process high risk fractures are the hip, wrist and spine.

Osteoporosis is easier to prevent than to cure!!!

HOW TO DETECT A HIGH RISK OF OSTEOPOROSIS?

There are factors that increase the risk of osteoporosis:

1. Low physical activity
2. Lack of calcium in food
3. Alcohol consumption
4. Smoking
5. Fragile build
6. Fractures in family members
7. Early menopause
8. Surgery to remove ovaries
9. Taking certain medications (such as cortisone)

IS THERE A CONNECTION BETWEEN CARDIOVASCULAR DISEASES AND MENOPAUSE?

In young women, estrogens protect the body from the development of atherosclerosis and coronary heart disease. With the onset of menopause, when hormone levels drop, the effect of this protective mechanism weakens, which contributes to the development of arterial hypertension, atherosclerosis, and also increases the risk of heart attacks and stroke.

DOES YOUR APPEARANCE CHANGE?

After 45 years, many women's hair turns gray and begins to lose elasticity and shine. Hair may begin to grow on other parts of the body (hips, face). The skin becomes less elastic and wrinkles begin to appear. The main reason for all these changes is low level female hormones- estrogens and progesterone.
The figure often changes. Many women approaching menopause notice unexplained weight gain and an increase in fat tissue, especially in the abdominal area, despite all efforts to lose weight. These changes are based on a deficiency of female sex hormones.

CAN SOMETHING BE CHANGED?

The quality of life of a woman during menopause largely depends on herself. Today every woman has the opportunity to choose. Of course, you can firmly endure all the manifestations of menopause, without taking any measures and telling yourself: aging is natural process

. However, if we recall the experience of previous generations, this does not add either strength or health. Currently, there is a real opportunity to help every woman in this matter, and this opportunity is in the hands of a doctor. It has now been established that the most effective way to solve problems associated with menopause and prevent it is late complications is hormone replacement therapy (HRT).

The decision to use sex hormone therapy is very individual and depends on the severity of menopausal symptoms and the presence of risk factors for osteoporosis. Like all

• medications , drugs for hormone replacement therapy have both indications and contraindications. (hot flashes, night sweats, sleep disturbances, mood changes, etc.)
• High risk of developing osteoporosis
• The appearance of urinary disorders (frequent urination, urinary incontinence during exercise)

FEMOSTON is a modern drug for the treatment of menopausal disorders and the prevention of postmenopausal osteoporosis. Femoston® contains natural estrogen - estradiol and dydrogesterone (Duphaston®) - an analogue of natural progesterone, which are of plant origin.

Femoston- these are 3 drugs to maintain a woman’s health at any stage of menopause.
Femoston quickly and effectively eliminates hot flashes, restores peace of mind and allows you to see life in all its colors!

FAQ

Is it possible to start treatment on your own if you have symptoms?

Treatment must be prescribed by a doctor. An additional examination before starting therapy will help you once again pay attention to your health. In addition, the gynecologist will help you choose the correct dosage of hormones in the drug and the regimen of administration.

How long can you take replacement medication? hormone therapy?

The duration of therapy is determined individually together with the attending physician. For elimination autonomic symptoms A short course of treatment (up to 6 months) may be sufficient. To prevent osteoporosis it is necessary long-term therapy(at least 3-5 years).

Are repeat visits to the doctor necessary?

Every woman over 45 years old needs regular visits to a gynecologist. When taking hormone replacement therapy drugs, you must visit a gynecologist every 3 months in the first year of use, then at least once a year.

What is low dose HRT regimen?

Modern drugs for hormone replacement therapy should contain low doses of estrogens - 1 mg estradiol. Increasing the dose of hormones to 2 mg is necessary only for the treatment of severe menopausal syndrome.

How to take Femoston?

Femoston is taken one tablet per day without interruption according to the calendar package. After finishing taking pills from one package, you must start a new package.

How to start therapy with Femoston?

If your menstrual cycle is irregular...
You need to start taking Femoston 1/10 or Femoston 2/10 on the first day of menstruation.
If you haven't had your period for 12 months...
You can start taking Femoston 1/5 on any convenient day.

What else can a woman do for her health?

1. Move more, walk, exercise
2. Limit smoking and alcohol intake
3. Watch your diet

And most importantly: allow yourself to be happy!!!

Femoston 2/10: instructions for use and reviews

Latin name: Femoston 2/10

ATX code: G03FB08

Active substance: estradiol (oestradiolum), dydrogesterone (dydrogesteronum)

Manufacturer: Solvay Pharmaceuticals (Netherlands), Abbott Laboratories S.A. (USA)

Updating the description and photo: 26.10.2018

Femoston 2/10 is an antimenopausal combined estrogen-gestagen drug.

Release form and composition

Femoston 2/10 is available in the form of film-coated tablets of two types - pink and light yellow color: round, biconvex, with “379” engraved on one side, when broken, the tablet core white with a rough structure (28 pieces in a blister - 14 pink tablets and 14 light yellow tablets; 1, 3 or 10 blisters in a cardboard pack).

• tablet Pink colour: estradiol hemihydrate – 2.06 mg, which is equivalent to the content of 2 mg estradiol;
• light yellow tablet: estradiol hemihydrate – 2.06 mg, which is equivalent to the content of 2 mg estradiol; dydrogesterone – 10 mg.

Auxiliary components: lactose monohydrate, colloidal silicon dioxide, hypromellose, magnesium stearate, corn starch.

Shell composition:

• pink tablet: opadry OY-6957 pink – macrogol 400, hypromellose, titanium dioxide (E171), red iron oxide, yellow iron oxide, black iron oxide, talc;
• light yellow tablet: opadry OY-02B22764 yellow – macrogol 400, hypromellose, yellow iron oxide, titanium dioxide (E 171), talc.

Pharmacological properties

Pharmacodynamics

Femoston 2/10 is an antimenopausal drug, the therapeutic effect of which is provided by a combination of two hormones. It is used as hormone replacement therapy (HRT) to prevent bone loss in the postmenopausal period and after oophorectomy.

Estradiol is an estrogen identical to endogenous estradiol, the main and most active female sex hormone. Taking estradiol makes it possible to compensate for estrogen deficiency in women upon the onset of menopause and reduce the symptoms of menopause at the beginning of treatment.

Dydrogesterone is a progestogen, its pharmacological effectiveness when taken orally is similar to the activity of progesterone. The presence of dydrogesterone in the tablet helps ensure complete secretory transformation of the endometrium, reducing the risk of developing endometrial hyperplasia, increased by the action of estrogen, during HRT.

Pharmacokinetics

After oral administration, absorption of Femoston 2/10 occurs in the gastrointestinal tract, where micronized estradiol and dydrogesterone are easily and quickly absorbed. The bioavailability of dydrogesterone is 28%.

Estrogen is found in bound and free states. Binding to plasma proteins: estradiol - up to 99% of the dose, of which with albumin - from 30 to 52%, with sex hormone binding globulin (SHBG) - from 46 to 69%; dydrogesterone and its metabolite – more than 90%.

In the liver, estradiol is metabolized to estrone and estrone sulfate. Both metabolites have estrogenic activity; estrone sulfate is characterized by enterohepatic recirculation.

The main metabolite of dydrogesterone is 20alpha-dihydrodydrogesterone (DHD), its maximum concentration in the blood plasma after taking the tablet occurs approximately 1.5 hours later. The plasma concentration of DHD significantly exceeds the initial concentration of dydrogesterone. The absence of estrogenic and androgenic effects is due to the characteristic feature characteristic of all dydrogesterone metabolites - maintaining the 4,6-dien-3-one configuration of the original substance and the absence of 17alpha-hydroxylation.

Estradiol passes into breast milk.

Elimination of estradiol and its metabolites is predominantly carried out by the kidneys in a state conjugated with glucuronic acid.

About 63% of the administered dose of dydrogesterone is excreted by the kidneys. Its total plasma clearance is 6.4 l/min. In urine, DGD is determined in to a greater extent in the form of a glucuronic acid conjugate.

Half-life: estradiol - 10-16 hours, dydrogesterone - 5-7 hours, DGD - 14-17 hours.

Dydrogesterone is completely eliminated after 72 hours.

With daily intake of Femoston 2/10, the equilibrium concentration in the blood plasma of estradiol occurs after approximately 5 days, dydrogesterone - after 3 days.

Taking multiple doses does not affect the pharmacokinetic properties of dydrogesterone and its main metabolite.

Indications for use

According to the instructions, Femoston 2/10 is indicated as HRT for conditions that are caused by estrogen deficiency in perimenopausal women (no earlier than six months after the last menstrual bleeding) and postmenopause.

In addition, the drug can be prescribed for the prevention of postmenopausal osteoporosis in women with a high risk of bone fractures, for whom the use of other drugs is contraindicated. medicines or if they are intolerant.

Contraindications

• untreated endometrial hyperplasia;
• vaginal bleeding of unknown etiology;
• breast cancer, including suspected;
• meningioma and other progestogen-dependent tumors, including suspected ones;
• endometrial cancer and other estrogen-dependent malignant tumors, including alleged ones;
• thrombosis (venous and arterial), including deep vein thrombosis (including medical history);
• thromboembolism, myocardial infarction, pulmonary embolism, cerebrovascular disorders of hemorrhagic and ischemic origin (including medical history);
• the presence of pronounced or multiple factors of venous or arterial thrombosis due to hereditary or acquired predisposition, including antithrombin III deficiency, protein C or S deficiency, the presence of lupus anticoagulant or antibodies to cardiolipin, prolonged immobilization, severe obesity (body weight index above 30 kg /m2), diseases coronary arteries or cerebral vessels, angina pectoris, transient ischemic attacks, atrial fibrillation, complicated lesions of the valvular apparatus of the heart;
• malignant neoplasms of the liver;
• porphyria;
• acute or chronic form liver diseases, until normalization functional indicators liver samples (including medical history);
• lactase deficiency, glucose-galactose malabsorption syndrome, galactose intolerance;
• pregnancy period;
• breast-feeding;
• individual intolerance to the components of the drug.

Continuation of Femoston 2/10 is contraindicated if liver dysfunction, jaundice, uncontrolled arterial hypertension, or new migraine-like headaches occur during HRT.

It is recommended to prescribe Femoston 2/10 with caution to women who have or have a history of the following diseases and conditions: arterial hypertension, endometriosis, uterine leiomyoma, risk factors for the occurrence of estrogen-dependent neoplasms (including close relatives with breast cancer), liver tumors of benign etiology, epilepsy, diabetes with or without vascular complications, systemic lupus erythematosus, cholelithiasis, bronchial asthma, strong headache, migraine, otosclerosis, endometrial hyperplasia.

Instructions for use of Femoston 2/10: method and dosage

Femoston 2/10 tablets are taken orally, regardless of meals, preferably always at the same time of day, convenient for the woman.

It is necessary to start taking the drug from the blister with pink tablets (marked with the number 1). After 14 days of taking tablets containing only estradiol (2 mg), followed by the use of light yellow tablets (marked with the number 2), which contain estradiol (2 mg) and dydrogesterone (10 mg). After 28 days, after finishing taking all the tablets from the current blister, therapy is continued by taking pink tablets from the new blister. HRT involves continuous use of the drug.

If you miss the next dose of Femoston 2/10 set time, the missed pill can be taken as soon as you remember, if the delay does not exceed 12 hours or the period since taking the previous pill is no more than 36 hours. Otherwise, it must be taken at the usual time the next day. Skipping the next dose of the drug increases the risk of breakthrough uterine bleeding.

Usually, HRT begins with the prescription of Femoston 1/10; if the therapeutic effect due to estrogen deficiency is insufficient, the dose of estradiol is increased using Femoston 2/10. In this case, namely when transitioning from continuous mode combination therapy, you can start taking a new drug any day.

When switching from another drug with a continuous sequential or cyclic treatment regimen, you must first complete the current cycle, and only then start taking Femoston 2/10.

Side effects

• general disorders: often - fatigue, malaise, weakness, peripheral edema;
• from the outside nervous system: very often – headache; often – dizziness, migraine;
• from the reproductive system and mammary glands: very often - tension in the mammary glands or their soreness; often - metrorrhagia, impaired vaginal secretion, bloody (spotting) discharge in postmenopause, pain in the lower abdomen, vaginal candidiasis, heavy menstrual-like bleeding, acyclic bleeding, scanty or absent menstrual-like bleeding, painful menstrual-like bleeding; uncommon – premenstrual-like syndrome, enlarged mammary glands, increased size of leiomyoma;
• from the outside of cardio-vascular system: infrequently – increased blood pressure, venous thromboembolism; rarely - myocardial infarction;
• from the hepatobiliary system: infrequently - pathologies of the gallbladder, impaired liver function, including in combination with malaise, abdominal pain, asthenia, jaundice;
• from the outside gastrointestinal tract: very often – abdominal pain; often – flatulence, nausea, vomiting;
• from the outside immune system: uncommon – hypersensitivity to estradiol and/or dydrogesterone;
• from the skeletal muscles and connective tissue: very often – pain in lumbar region backs;
• dermatological reactions: often - allergic reactions, in the form skin rash, itching, urticaria; rarely - angioedema, vascular purpura;
• mental disorders: often – nervousness, depression; infrequently – libido disturbance;
• infectious diseases: infrequently – cystitis;
• other: often – increase in body weight; infrequently – decrease in body weight.

In addition, against the background of combined estrogen-gestagen therapy with the use of Femoston 2/10, the following adverse events may develop:

• from the body as a whole: ovarian cancer, endometrial cancer, meningioma and other neoplasms of malignant, benign or unspecified etiology;
• from the reproductive system and mammary glands: cervical erosion, fibrocystic mastopathy;
• from the cardiovascular system: arterial thromboembolism;
• from the gastrointestinal tract: with hypertriglyceridemia - pancreatitis;
• from the nervous system: chorea, provoking epilepsy attacks, risk of developing dementia in women who begin hormone replacement therapy over the age of 65 years;
• from the hematopoietic system: hemolytic anemia;
• from the immune system: systemic lupus erythematosus;
• from the organs of vision: increased curvature of the cornea, hypersensitivity to contact lenses;
• from connective tissue and skeletal muscles: muscle cramps lower limbs;
• from the outside genitourinary system: urinary incontinence;
• laboratory indicators: increased levels of thyroid hormones;
• dermatological reactions: erythema nodosum, erythema multiforme, chloasma and/or melasma;
• from the side of metabolism: hypertriglyceridemia;
• others: in patients with porphyria – worsening of the disease.

Overdose

Symptoms: abdominal pain, dizziness, nausea, vomiting, weakness, drowsiness, withdrawal bleeding, breast tenderness.

Treatment: symptomatic therapy.

special instructions

Femoston 2/10 should only be prescribed to women with symptoms that cause a significant deterioration in their quality of life, and HRT should be continued until the risk of side effects outweighs the benefits of treatment. Extra caution should be used in patients over 65 years of age, since experience with the drug at this age is limited.

The most common adverse events that occur with the combination of estradiol and dydrogesterone include tension and tenderness of the mammary glands, abdominal pain, headache, and back pain.

Before starting or resuming therapy, a woman must undergo a general and gynecological examination and mammography. To take into account possible contraindications and condition, the prescription of Femoston 2/10 should be based on the patient’s complete medical and family history. Guided by clinical picture, the doctor should inform the woman about all the risks associated with hormonal therapy and about those changes in the mammary glands that require consultation with a doctor.

Since HRT is carried out over a long period of time, examinations are recommended during treatment. The doctor determines their frequency and nature for each patient individually, but the frequency of examinations should not be less than once every six months.

The influence of estrogens on results should be considered laboratory tests to determine glucose tolerance, study liver and thyroid function.

Compared with women not receiving estrogen monotherapy, its use in patients increases the risk of developing endometrial hyperplasia or cancer from 2 to 12 times, depending on the duration and dose of the drug. Moreover, it remains elevated for another 10 years after estrogen withdrawal. Cyclic use of progestogen reduces elevated by estrogen risk of endometrial hyperplasia and cancer. For timely diagnosis of these diseases, it is advisable to use ultrasound screening and histological examination. At the beginning of treatment, breakthrough or spotting may occur. bloody discharge from the vagina. If such bleeding occurs after several months of therapy or after discontinuation of Femoston 2/10, to exclude a malignant neoplasm, it is necessary to diagnose their cause, including performing an endometrial biopsy.

HRT increases the risk of developing deep vein thrombosis and pulmonary embolism by almost 3 times, especially during the first year of hormone use. Women whose close relatives (mother, father) at a young age had thromboembolic complications, or with a history of recurrent miscarriage, a hemostasis study is necessary. During anticoagulant therapy, the prescription of Femoston 2/10 is possible only if the benefits of HRT outweigh the potential risk of thromboembolism.

The use of HRT should be discontinued 1–1.5 months before planned surgery with long-term subsequent immobilization. You can resume hormonal therapy only after full recovery woman's mobility.

To the symptoms venous thromboembolism This includes swelling of the lower extremities, pain, shortness of breath, and sudden chest pain. If they develop while using Femoston 2/10, you should immediately consult a doctor and stop taking the drug.

The incidence of breast cancer diagnosis, which increases with the use of estrogen monotherapy or a combination of estrogen and progestogen, returns to its original level within 5 years after cessation of therapy. The risk of developing breast cancer depends on the duration of therapy and can double after 5 years of combined estrogen-progestogen HRT. Timely diagnosis of breast cancer can make breast engorgement difficult during HRT.

There is a risk of developing ovarian cancer, but it is significantly lower than the risk of breast cancer.

The use of Femoston 2/10 increases the risk of ischemic stroke by 1.5 times; treatment does not affect the occurrence of hemorrhagic stroke.

Since estrogens can retain fluid in the body, this can worsen the condition in patients with impaired kidney and heart function.

With hypertriglyceridemia that occurs while taking Femoston 2/10, the risk of developing pancreatitis increases.

HRT does not improve cognitive function. The increased risk of developing dementia should be taken into account when prescribing the drug to women over 65 years of age.

Femoston 2/10 does not have contraceptive properties.

Impact on the ability to drive vehicles and complex mechanisms

It is recommended to be careful when working with complex mechanisms and operating vehicles, since the drug may cause dizziness, drowsiness and other side effects, affecting the speed of psychomotor reactions.

Use during pregnancy and lactation

The use of Femoston 2/10 is contraindicated during pregnancy and lactation.

If you conceive while using a hormonal drug, treatment should be discontinued immediately.

For impaired renal function

Since estrogens can retain fluid in the body, this can worsen the condition if the patient's kidney function is impaired.

For liver dysfunction

The use of Femoston 2/10 is contraindicated in patients with malignant neoplasms liver, with chronic or acute forms of liver dysfunction (including medical history), porphyria.

Use in old age

Experience with the use of Femoston 2/10 in women over 65 years of age is limited.

Drug interactions

Simultaneous use of Femoston 2/10 with other medicinal substances/preparations:

• anticonvulsants (carbamazepine, phenobarbital, phenytoin), antimicrobial agents (nevirapine, rifabutin, rifampicin, efavirenz), ritonavir, nelfinavir, Hypericum perforatum (St. John's wort) preparations: enhance the metabolism of estrogens and gestagens, clinical manifestation which may increase the intensity of bloody discharge from the vagina;
• fentanyl, tacrolimus, theophylline, cyclosporine: may significantly increase their plasma concentration levels.

Analogs

Analogues of Femoston 2/10 are: Femoston 1/5 Conti, Femoston 1/10, Femoston Mini, Klimonorm, Trisequence, Divina, Kliogest.

Terms and conditions of storage

Store at temperatures up to 30 °C. Keep away from children.

Shelf life – 3 years.

Thank you

The site provides background information for informational purposes only. Diagnosis and treatment of diseases must be carried out under the supervision of a specialist. All drugs have contraindications. Consultation with a specialist is required!

Femoston is a hormone replacement therapy drug that is used to treat various natural changes in a woman’s body caused by the onset of menopause or removal of the ovaries (surgical castration). Femoston ensures the entry into the woman’s body of sex hormones, which, as a result of menopause or surgical castration, are produced by the ovaries and adipose tissue in insufficient quantities and, thereby, maintain normal condition and functioning various organs and systems. Femoston eliminates various disorders caused by deficiency of sex hormones, such as vegetative, psycho-emotional and sexual disorders, and also prevents ischemic heart disease and osteoporosis.

Types, names, release forms and composition of Femoston

Currently, three varieties of the drug Femoston are produced - these are Femoston 1/10, Femoston 2/10 and Femoston 1/5 (Conti). All three varieties are available in a single dosage form – pills for oral administration, and differ from each other only in the dosage of active components. Femoston 1/5 tablets are correctly called “Femoston Conti 1/5”, but in everyday speech they are often referred to as “Femoston 1 5” or “Femoston Conti”. Tablets Femoston 1/10 and Femoston 2/10 are often written and called “Femoston 1 10” and “Femoston 2 10”. Femoston 1, Femoston 2 and Femoston 5 tablets do not exist. The types of Femoston tablets differ from each other only in the dosage of the active substance in the tablets.

All varieties of Femoston include estradiol (estrogen hormone) and dydrogesterone(progesterone hormone) in various dosages.

Femoston 1/5 is available in packs of 28 tablets, each of which contains 1 mg of estradiol and 5 mg of dydrogesterone. The tablets are orange-pink in color, have a round, biconvex shape and are engraved with “379” on one side and “S” on the other.

Femoston 1/10 Available in packs of 28 tablets. Each package contains 14 tablets of two types - white and gray. White tablets contain 1 mg of estradiol, and gray tablets contain 1 mg of estradiol + 10 mg of dydrogesterone. Both the white and gray tablets are round, biconvex in shape and have "379" engraved on one side.

Femoston 2/10 Available in packs of 28 tablets, of which there are two varieties - pink and light yellow. There are the same quantity of both types of tablets, that is, one pack contains 14 pieces, both pink and light yellow. Each pink tablet contains 2 mg of estradiol, and each light yellow tablet contains 2 mg of estradiol + 10 mg of dydrogesterone. Both types of tablets are the same size, rounded biconvex shape and have "379" engraved on one side.

As auxiliary components, all types of tablets of the three varieties of Femoston (pink-orange, white, gray, pink, light yellow) contain the same substances, such as:

• Hypromellose;
• Magnesium stearate;
• Colloidal silicon dioxide;
• Lactose monohydrate;
• Talc;
• Titanium dioxide;
• Polyethylene glycol 400;
• Iron oxides black, red and yellow (to give color to tablets).

Therapeutic effect

All varieties of Femoston have the same therapeutic effect, and different dosages active hormones allow you to choose for every woman optimal drug, best suited for her.

Femoston is a combined, modern, low-dose hormonal drug, therapeutic effects which is caused by the constituents estradiol and dydrogesterone.

Estradiol, which is part of Femoston, is identical to the natural one normally produced by a woman’s ovaries. That is why it replenishes the deficiency of estrogen in the body when it is insufficiently produced during menopause or almost completely absent during castration syndrome. Estrogens in women in menopause or after removal of the ovaries ensure smoothness, elasticity and slow aging of the skin, slow down hair loss, and cause hair production. vaginal lubrication, preventing dryness and discomfort during sexual intercourse, and also prevent atherosclerosis and osteoporosis. In addition, estradiol eliminates specific manifestations of menopause or castration syndrome, such as hot flashes, sweating, sleep disturbances, excitability, dizziness, headaches, atrophy of the skin and mucous membranes, etc.

Dydrogesterone is a progesterone hormone that ensures endometrial growth in the second half menstrual cycle among women. When taken as part of Femoston, dydrogesterone reduces the risk of developing endometrial hyperplasia or cancer, which increases with the use of estrogens. This progesterone hormone does not have any other effects, and is included in Femoston specifically to reduce the risk of endometrial hyperplasia and cancer, which increases due to estradiol intake.

Femoston - indications for use

Indications for use for all three varieties of Femoston (1/10, 2/10 and 1/5) are the same:
1. Hormone replacement therapy for specific menopausal or castration syndrome in women, manifested by hot flashes, sweating, palpitations, sleep disturbances, excitability, nervousness, vaginal dryness and other symptoms of estrogen deficiency. Femoston 1/10 and 2/10 can be started to be used six months after the last menstruation, and Femoston 1/5 - only a year later;
2. Prevention of osteoporosis and increased bone fragility in women during menopause with intolerance to other drugs intended to maintain normal bone mineralization, prevent calcium deficiency and treat this pathology.

Instructions for use

Femoston 1/5 – instructions (how to take)

Femoston 1/5 should be taken one tablet every day, preferably at the same time, regardless of meals. After finishing the tablets from one pack, start the next one immediately, without taking any breaks.

If on some day a woman forgot to take another Femoston 1/5 tablet, but less than 12 hours have passed from the scheduled time, then she should take it as quickly as possible. If more than 12 hours have passed since the pill was supposed to be taken, then you need to skip it and next day Take the tablets as usual until the end of the pack. You should not take two tablets at once to compensate for a missed dose. If a woman forgot to take a pill, then while taking the current pack she has an increased risk of bleeding and spotting from the genital tract.

The duration of use of the drug is determined individually, based on the speed of normalization of the condition and the disappearance of menopausal symptoms. Usually the drug is taken for at least 3 to 6 months without interruption. In principle, Femoston 1/5 is suitable for long-term continuous use, that is, tablets can be taken for several years in a row without taking any breaks.

If Femoston 1/5 is not effective in relieving the symptoms of menopause, then you can switch to Femoston 1/10 or Femoston 2/10, which contain a higher dosage of hormones. Depending on how you feel and the effectiveness of treatment, the dosage of Femoston can be changed again in the future.

If a woman is already taking any estrogen-progestogen drug (for example, Femoston 1/10, Femoston 2/10, Angeliq, Cliogest, Climodien, Indivina, etc.) and wants to replace it with Femoston 1/5, then she should first finish her drink Completely started packaging of the medicine. Then, without taking any break, the next day after taking last pill from the package of estrogen-progestagen drug, you should start taking Femoston 1/5 tablets.

If a woman is taking an estrogen-progestin drug (for example, Trisequence, Divisek, etc.) and wants to switch to Femoston 1/5, then this can be done any day. That is, it is not necessary to finish the started pack of estrogen-progestogen tablets, it is enough just to start taking Femoston 1/5 the next day.

Femoston 1/10 and Femoston 2/10 – instructions (how to take)

A pack of Femoston 1/10 contains 14 white and 14 gray tablets, and a pack of Femoston 2/10 contains 14 pink and 14 light yellow tablets, which are taken regardless of food. In each new pack of Femoston 1/10, first take all the white tablets, one piece per day, preferably at the same time. Then take all the gray tablets, 1 piece per day, also preferably at the same time. Do the same with Femoston 2/10, first taking all the pink tablets, one per day, and then the light yellow ones, also one per day.

After finishing one pack of Femoston 1/10 or Femoston 2/10, and opening a new one, again take all white tablets from 1/10 or pink tablets from 2/10, and then gray tablets from 1/10 or light yellow tablets from 2/10. 10, one piece per day. There are no breaks between packs, that is, after finishing one, start taking pills from a new one the next day.

Women who have not stopped menstruating should start taking Femoston 1/10 or Femoston 2/10 on the first day of menstruation. If the menstrual cycle is irregular, then before starting to take Femoston 1/10 or 2/10, you should take progestagen drugs (for example, Veraplex, Gestanin, Gormofort, Duphaston, Levonova, etc.) for two weeks, which will provide withdrawal bleeding in order to remove the uterine cavity of all remnants of the endometrium. If a woman’s menstruation stopped more than six months ago, then she can start taking Femoston 1/10 and 2/10 any day.

If a woman forgot to take a pill and less than 12 hours have passed since her usual dose, then she should take the missed pill. If more than 12 hours have passed since the usual dose, then the missed tablet is removed from the pack and thrown away, and the next day the next tablet is taken according to the schedule. You should not take two tablets at the same time in order to eliminate the omission. While taking a pack with a missed pill, a woman has an increased risk of bleeding from the genital tract.

The duration of use of Femoston 1/10 and Femoston 2/10 is determined individually, depending on the speed of normalization of the condition and relief of menopausal syndrome. The drugs are suitable for long-term use and can be used for several years without interruption. If the treatment is not effective enough, you can replace the drug with another one or choose Femoston with a lower or higher dosage of hormones. Usually, hormone replacement therapy is started with Femoston 1/10, and then, depending on the reaction of the woman’s body, she is left on this type of drug or transferred to Femoston 1/5 or Femoston 2/10.

If a woman wants to switch to taking another drug with 2 or 3 types of tablets, then she should first finish the started pack of Femoston 1/10 Femoston 2/10. Then, without any break, the next day after taking the last tablet from the pack of Femoston 1/10 or Femoston 2/10 you need to start taking another drug.

If a woman wants to switch to taking Femoston 1/10 or Femoston 2/10 from any other drug containing only one type of tablet, then this can be done at any time. That is, you don’t need to finish a pack of another drug, just any day instead of old tablet drink the first pack of Femoston 1/10 or Femoston 2/10.

special instructions

All three varieties of Femoston are contraindicated for use during pregnancy and breastfeeding. If pregnancy occurs accidentally while taking Femoston, you should immediately stop taking the drug. The issue of continuing pregnancy should be decided individually with a gynecologist.

Since estrogens promote fluid retention in the body and the formation of edema, all three types of Femoston should be used with caution in women suffering from kidney disease, renal or heart failure. During the entire period of use of any type of Femoston, kidney and heart function should be monitored and the woman’s condition should be monitored.

Femoston 2/10 should not be used by women suffering from acute or chronic liver diseases at any stage. And Femoston 1/10 and Femoston 1/5 can be used for liver diseases, but only after liver test parameters (AST, ALT and alkaline phosphatase activity) are normalized.

While using Femoston, the risks and benefits should be assessed at least once a year, as well as correlate them with each other, and based on this, make a decision on continuing or stopping hormone replacement therapy. Taking any type of Femoston continues as long as the benefits outweigh the risks.

Before starting to use any type of Femoston, it is necessary to carefully find out all existing and past diseases, as well as conduct an examination of the condition of the genital organs and mammary glands. If there are any benign neoplasms in the uterus, ovaries or mammary glands, then Femoston cannot be taken. If any nodes or lumps form in the chest while taking medications, you should immediately consult a doctor.

During the entire period of taking Femoston, women suffering in the present or having suffered in the past the following diseases, must visit a doctor at least once every three months:

• Endometriosis;
• High risk of thrombosis or thromboembolism;
• Presence of breast cancer in blood relatives (mother, sister, grandmother, etc.);
• Hypertonic disease;
• Hepatocellular adenoma;
• Cholelithiasis;
• Severe obesity (BMI over 30);
• Migraine;
• Severe headache;
• Systemic lupus erythematosus;
• Bronchial asthma;
• Porphyria;
• Epilepsy;

In women who have suffered from the listed diseases in the past or present, their symptoms may intensify while taking Femoston. If a woman has the listed diseases, the risk of developing complications of hormone replacement therapy increases significantly, such as breast cancer, thromboembolism, ischemic disease heart disease, heart attack, stroke, etc., and that is why this category of women needs to constantly monitor their condition by visiting a doctor at least once a quarter.

You should be aware that taking Femoston or any hormone replacement therapy drug containing estrogen slightly increases the risk of developing endometrial and breast cancer. Therefore, women who have not had their uterus and mammary glands removed should be careful and wary of possible cancer endometrium during the entire period of taking Femoston. The risk of developing cancer increases the longer you take Femoston. In addition, while taking Femoston in women, the risk of coronary artery disease and stroke increases. However, the risk of developing stroke and ischemic heart disease is more influenced by the woman’s age and her existing chronic diseases, but it does not depend at all on the duration of use of Femoston.

The risk of venous thromboembolism increases most significantly during therapy with any type of Femoston in women. Moreover, the risk of thromboembolism is highest during the first year of treatment, and in subsequent years, on the contrary, it decreases. Therefore, women who have increased risk venous thromboembolism, can take Femoston only under the supervision of a doctor and under close supervision. If any of the blood relatives has a thrombolytic defect (for example, deficiency of antithrombin, protein C, protein S, etc.), then the woman should not take Femoston.

Since any extensive surgery is accompanied by a risk of thromboembolism, then 4–6 weeks before the procedure it is necessary to stop taking Femoston. It will be possible to resume taking Femoston only after motor activity is completely restored after the operation.

During the entire period of Femoston therapy, the concentration of triglycerides, thyroid-binding globulin, corticoid-binding globulin and sex hormone-binding globulin, as well as alpha-1-antitrypsin and ceruloplasmin in the blood may increase. However, this does not lead to an increase in the concentration of circulating active hormones.

Femoston does not improve mental abilities and is not a contraceptive drug.

At the beginning of treatment with any type of Femoston, a woman may develop breakthrough bleeding or spotting. If bleeding or spotting occurs, you should discontinue Femoston, consult a doctor and undergo an examination to identify tumors or endometrial hyperplasia.

If jaundice, migraine-like headaches, liver dysfunction, severe increase in blood pressure, pregnancy or symptoms of troboembolism (painful swelling of the legs, sharp chest pain, shortness of breath, blurred vision) develop, you must immediately stop taking the drug and consult a doctor.

Overdose

Cases of overdose with Femoston 1/5 have not been registered, however, theoretically, if this happens, there may be an increase in side effects.

An overdose of Femoston 1/10 and Femoston 2/10 is possible, and it is manifested by the development of nausea, vomiting, drowsiness and dizziness. There is no specific antidote, therefore, in case of an overdose of Femoston, it is necessary to perform a gastric lavage, give the woman a sorbent (for example, activated carbon, Polyphepan, Polysorb, etc.) and then, if necessary, eliminate various symptoms, supporting normal work vital organs.

Impact on the ability to operate machinery

Any type of Femoston does not affect the ability to operate machinery, however, women who take hormone replacement therapy drugs should be careful when driving a car or working with machinery and machines.

Interaction with other drugs

Drugs that enhance the activity (inducers) of microsomal liver enzymes (for example, barbiturates, Phenytoin, Rifampicin, Carbamazepine, Rifabutin, Oxcarbazepine, Topiramate, Felbamate, Nevirapine, Efavirenes, etc.) reduce the severity of the effects of Femoston. The drugs Ritonavir and Nelfinavir, despite the fact that they are inducers of microsomal oxidation, do not reduce the effects of Femoston.

Any herbal preparations containing St. John's wort or its parts accelerate the excretion of Femoston components, and thereby weaken its therapeutic effect.

Femoston slows down the elimination of Tacrolimus, Fentanyl, Theophylline and Cyclosporine A from the body, so the dosages of these drugs should be reduced in order to prevent overdose and poisoning.

Femoston when planning pregnancy

IN last years Practicing gynecologists often prescribe the combination Femoston + Duphaston to women experiencing problems conceiving. Femoston is not indicated for use in the treatment of infertility, but in practice it is prescribed to women for normalization hormonal levels and an increase in the thickness of the endometrium, which significantly increases the likelihood of pregnancy. In such situations, doctors use pharmacological properties drug to achieve a certain effect in conditions that are not an indication for use. This practice of using drugs for other purposes is found all over the world and is called off-label prescriptions. Let's consider why Femoston promotes pregnancy and in what cases its use is justified in case of difficulties with conception.

Since Femoston contains natural estrogens and progesterone hormone, it has the ability to replenish estrogen deficiency and enhance the growth of the endometrium, making it thicker, denser and more blood-filled. Replenishing estrogen deficiency helps restore ovulation, and an additional dosage of progesterone improves the growth of the endometrium, making it thick enough for attachment ovum. This means that Femoston can help women who are unable to conceive due to too much pregnancy to become pregnant. thin endometrium or existing estrogen deficiency.

However, Femoston therapy is not very effective, since pregnancy occurs in only half of the woman after stopping the drug, since there is no ovulation during the course of treatment. In addition, Femoston causes numerous side effects in women that are poorly and difficult to tolerate. Therefore, many gynecologists consider the use of Femoston to treat infertility unjustified. This category of doctors believes that in such situations women should take special drug, containing estrogens, and in the second half - Duphaston.

When planning a pregnancy, Femoston is usually prescribed in a dosage of 2/10, and it is recommended to take it according to the instructions, that is, one tablet per day, regardless of meals, preferably at the same time. Women need to drink all the tablets in the pack. Moreover, first they take all 14 pink tablets, then 14 light yellow tablets. After finishing taking pills from one pack, the next one is started without any break, and so on until the course of therapy is completed. Quite often, in addition to Femoston, doctors prescribe Duphaston, which should be taken only in combination with light yellow tablets from each pack, that is, in the second half of the menstrual cycle. This means that at first the woman takes only pink tablets from each pack, and then light yellow Femoston + Duphaston tablets.

Femoston should be taken on the first day of the next menstrual cycle. If menstruation is irregular, it is recommended to start taking pink pills Femoston on the day of the expected start of menstruation.

Side effects of Femoston

Different types of Femoston can provoke the same side effects with different frequencies. In addition, some side effects are unique to one form or another of Femoston. Therefore, we present the side effects of each type of Femoston indicating the frequency of their occurrence in the table.

Incidence of side effects	Side effects of Femoston 1/5	Side effects Femoston 1/10	Side effects of Femoston 2/10
Common (more than one in a hundred women, but less than one in ten)	Migraine; Headache; Asthenia; Nausea; Stomach ache ; Bloating; Spasms in the calf muscles; Tension and tenderness of the mammary glands; Uterine bleeding ; Pain in the pelvis; Change in body weight (decrease or increase).
	Spotting		Spotting
Uncommon (more than one in a thousand women, but less than one in a hundred)	; Contact lens intolerance; Impaired liver function, manifested by jaundice, asthenia and pain in the upper abdomen; Increase in breast size.
	Premenstrual syndrome	Breast tension syndrome before menstruation
	Very rare (occurs in less than one woman in 10,000)	Hemolytic anemia; Allergic reactions; Chorea; Myocardial infarction; Stroke; Vomit; Quincke's edema; Erythema nodosum multiforme; Vascular purpura; Chloasma or melasma; Worsening of the course of porphyria.

Contraindications to the use of Femoston

All Femoston drugs (1/5, 1/10 and 2/10) have absolute and relative contraindications for use. TO absolute contraindications refer to conditions in which drugs cannot be used under any circumstances. TO relative contraindications include conditions in which the use of Femoston is undesirable, but possible under close medical supervision and with caution.

Absolute contraindications to the use of all three types of Femoston are given in the table.

Absolute contraindications to the use of Femoston 1/5	Absolute contraindications to the use of Femoston 1/10 and Femoston 2/10
Cerebrovascular disorders	Existing or recent arterial thromboembolism (for example, heart attack, stroke, coronary artery disease, etc.)
	Untreated endometrial hyperplasia
	Porphyria
	Known or suspected progestogen-dependent tumors, such as meningioma
Pregnancy or suspected pregnancy
Breast-feeding
Detected breast cancer
Suspicion of breast cancer
Previous history of breast cancer
Endometrial cancer detected or suspected
Bleeding from the genital tract of unknown cause
Acute deep vein thrombosis or pulmonary embolism in the past
Hypersensitivity to the components of the drug
Acute or chronic liver diseases in the present or suffered in the past (the drug can be used after normalization of laboratory parameters of liver function)
Detected thrombophilic disorders (deficiency of protein C or S or antithrombin)
Age under 18

Relative contraindications are the same for all three forms of Femoston, and these include the following diseases or conditions that a woman currently has or has had in the past:

Pregnancy;

The appearance of any side effect.

Femoston - analogues

Femoston does not have synonymous drugs that contain the same active substances in identical dosages. However, on the domestic pharmaceutical market there is a fairly wide range of different drugs analogues of Femoston, which have a similar therapeutic effect, but contain other active substances. Below is a list of Femoston analogs that have the same anti-menopausal effect and contain a combination of estrogen and progesterone hormones as active components:
1. Activel tablets;
2. Angelique tablets;
3. Gynodian Depot solution for injection;
4. Divitren tablets;
5. Indivina tablets;
6. Clymene tablets;
7. Climodien tablets;
8. Kliogest tablets;
9. Pauzogest tablets;
10. Triaklim tablets;
11. Trisequence tablets;
12. Eviana tablets;
13. Revmelid tablets;
14. Cyclo-Proginova dragee.

To eliminate the symptoms of menopause, you can use not only hormonal agents, but also various herbal and biological active additives to foods that contain only natural plant and animal ingredients. Such non-hormonal analogues of Femoston for their anti-menopausal effect include the following drugs:

• Inoclim;
• Klimadinon UNO;
• Klimalanin;
• Livial;
• Femiwell;
• Feminal;
• Estrovel, etc.